The short version
- Why people research itFollistatin increase / myostatin reduction for muscle growth (harsh — bloodwork advised).
- What the evidence isNo human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
- What to watchTesticular shrinkage or loss of libido.
How YK-11 works
Start with the name, because the name is the mechanism and this site's own card gets the class wrong. YK11 is (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester Kanno 2011.
What it does at the receptor is stranger than the marketing, and more interesting. In an androgen-response-element luciferase reporter, YK11 behaves as a partial agonist of the androgen receptor. It accelerates AR translocation into the nucleus.
- Oral
- Injectable
On the goal map: Myostatin & activin inhibition (Build muscle & strength)
Where to get YK-11
When a vetted partner does, the link and code go here.
Research on YK-115 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
No completed human trial
Correlative data
No human trials, no human series, and it is on WADA's prohibited list — which is a statement about detectability and intent rather than safety.
Community reports describe strength gains alongside the joint discomfort, lipid changes and suppression associated with androgenic compounds.
How the mechanism reads
Usually described as a SARM; structurally it is a steroidal compound — a gene-edited derivative of DHT — which matters because the 'non-steroidal' framing that makes SARMs sound benign does not apply.
MechanisticIt acts as a partial androgen receptor agonist and is proposed to inhibit myostatin via follistatin induction, based on cell-culture work in myoblasts. That is the entire evidence base — one cell line — and the androgenic activity predicts hepatic and lipid effects that the myostatin story tends to leave out.
Experimental, animal or cell
Sources
- Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, Yamaguchi A, Tominaga N, Kohra S, Arizono K, Inouye Y. (17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor.. Biol Pharm Bull 2011 · PMID 21372378
- Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression.. Biol Pharm Bull 2013 · PMID 23995658
- Lee SJ, Gharbi A, Shin JE, Jung ID, Park YM. Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis.. Biochem Biophys Res Commun 2021 · PMID 33588136
- Mohamed WT, Jahagirdar V, Fatima I, Ahmed MK, Jaber F, Wang K, Hassan A, Ewing E, Clarkston W, Likhitsup A. Selective Androgen Receptor Modulators (SARMs)-Induced Liver Injury: A Case Report and Review of Literature.. Cureus 2023 · PMID 36945289
- Leciejewska N, Jedrejko K, Gomez-Renaud VM, Manriquez-Nunez J, Muszynska B, Pokrywka A. Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.. Eur J Clin Pharmacol 2023 · PMID 38059982
YK-11 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Prostate or other hormone-sensitive cancer: androgen receptor activation feeds it.
- Wanting children soon: androgen signaling shuts down the pituitary and sperm output.
- Liver disease: steroidal compounds strain the liver.
- Heart disease or high LDL: androgenic compounds lower HDL.
- Under 18: puberty hormones are still setting.
What’s expected
- Muscle fullness, as it partly activates the androgen receptor and lifts follistatin.
- Testosterone and LH fall as the axis is suppressed.
- Acne or oily skin.
- Lower HDL cholesterol.
Watch for
- Testicular shrinkage or loss of libido.
- Yellow eyes or dark urine while using YK-11.
- Chest pain while using YK-11.
- Mood crashes.
Labs that tell you it’s working
- Total & Free Testosterone (ECLIA/Direct)
- LH & FSH
- Lipid Panel
- Comprehensive Metabolic Panel (CMP)
YK-11 is a steroidal partial androgen receptor agonist that also raises follistatin; test-tube and anecdotal data only, and it is SARM-like.
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
YK-11 FAQ4 common questions
- Is YK-11 approved for human use?
- No. YK-11 is a research compound. No completed randomized human trial has given it yet.
- What is YK-11 researched for?
- Follistatin increase / myostatin reduction for muscle growth (harsh — bloodwork advised).
- Which labs show whether it's doing anything?
- Total & Free Testosterone; LH & FSH; Lipid Panel; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for YK-11: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



